IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease

Jesse Mitchell, Vesselin Dimov, Robert G. Townley

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

It is widely accepted that T-helper 2 cell (Th2) cytokines play an important role in the maintenance of asthma and allergy. Emerging evidence has highlighted the role of IL-13 in the pathogenesis of these diseases. In particular, IL-13 is involved in the regulation of IgE synthesis, mucus hypersecretion, subepithelial fibrosis and eosinophil infiltration, and has been associated with the regulation of certain chemokine receptors, notably CCR5. Thus, targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. Pharmaceutical and biotechnology companies are researching various strategies, based on this approach, aimed at binding IL-13, increasing the level of the IL-13 decoy receptor, IL-13Rα2, or blocking the effect of the chemokine receptor CCR5. This review focuses on the therapeutic potential of anti-IL-13 agents and their role in the treatment of asthma and allergy.

Original languageEnglish
Pages (from-to)527-534
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Volume11
Issue number5
StatePublished - May 2010

Fingerprint

Interleukin-13 Receptors
Interleukin-13
Asthma
Hypersensitivity
Chemokine Receptors
Therapeutics
Th2 Cells
Mucus
Biotechnology
Eosinophils
Immunoglobulin E
Fibrosis
Maintenance
Cytokines
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. / Mitchell, Jesse; Dimov, Vesselin; Townley, Robert G.

In: Current Opinion in Investigational Drugs, Vol. 11, No. 5, 05.2010, p. 527-534.

Research output: Contribution to journalReview article

Mitchell, Jesse ; Dimov, Vesselin ; Townley, Robert G. / IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. In: Current Opinion in Investigational Drugs. 2010 ; Vol. 11, No. 5. pp. 527-534.
@article{76d1b1643a8f44d99968ab9ec55b968f,
title = "IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease",
abstract = "It is widely accepted that T-helper 2 cell (Th2) cytokines play an important role in the maintenance of asthma and allergy. Emerging evidence has highlighted the role of IL-13 in the pathogenesis of these diseases. In particular, IL-13 is involved in the regulation of IgE synthesis, mucus hypersecretion, subepithelial fibrosis and eosinophil infiltration, and has been associated with the regulation of certain chemokine receptors, notably CCR5. Thus, targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. Pharmaceutical and biotechnology companies are researching various strategies, based on this approach, aimed at binding IL-13, increasing the level of the IL-13 decoy receptor, IL-13Rα2, or blocking the effect of the chemokine receptor CCR5. This review focuses on the therapeutic potential of anti-IL-13 agents and their role in the treatment of asthma and allergy.",
author = "Jesse Mitchell and Vesselin Dimov and Townley, {Robert G.}",
year = "2010",
month = "5",
language = "English",
volume = "11",
pages = "527--534",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease

AU - Mitchell, Jesse

AU - Dimov, Vesselin

AU - Townley, Robert G.

PY - 2010/5

Y1 - 2010/5

N2 - It is widely accepted that T-helper 2 cell (Th2) cytokines play an important role in the maintenance of asthma and allergy. Emerging evidence has highlighted the role of IL-13 in the pathogenesis of these diseases. In particular, IL-13 is involved in the regulation of IgE synthesis, mucus hypersecretion, subepithelial fibrosis and eosinophil infiltration, and has been associated with the regulation of certain chemokine receptors, notably CCR5. Thus, targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. Pharmaceutical and biotechnology companies are researching various strategies, based on this approach, aimed at binding IL-13, increasing the level of the IL-13 decoy receptor, IL-13Rα2, or blocking the effect of the chemokine receptor CCR5. This review focuses on the therapeutic potential of anti-IL-13 agents and their role in the treatment of asthma and allergy.

AB - It is widely accepted that T-helper 2 cell (Th2) cytokines play an important role in the maintenance of asthma and allergy. Emerging evidence has highlighted the role of IL-13 in the pathogenesis of these diseases. In particular, IL-13 is involved in the regulation of IgE synthesis, mucus hypersecretion, subepithelial fibrosis and eosinophil infiltration, and has been associated with the regulation of certain chemokine receptors, notably CCR5. Thus, targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. Pharmaceutical and biotechnology companies are researching various strategies, based on this approach, aimed at binding IL-13, increasing the level of the IL-13 decoy receptor, IL-13Rα2, or blocking the effect of the chemokine receptor CCR5. This review focuses on the therapeutic potential of anti-IL-13 agents and their role in the treatment of asthma and allergy.

UR - http://www.scopus.com/inward/record.url?scp=77952126162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952126162&partnerID=8YFLogxK

M3 - Review article

VL - 11

SP - 527

EP - 534

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 5

ER -